AbbVie Inc. (0QCV.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:14PM BST
| Previous close | 147.37 |
| Open | 150.11 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 146.93 - 147.40 |
| 52-week range | 146.93 - 147.40 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 2.191B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?
Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.
- Simply Wall St.
With EPS Growth And More, AbbVie (NYSE:ABBV) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
- Motley Fool
If You Invested $25,000 in Abbott Laboratories in 2013, This Is How Much You Would Have Today
It has been more than nine years since Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV). The move has worked out well for AbbVie, which today has a larger market capitalization than Abbott's. But how has it worked out for Abbott, and would its investors have made the right move if they bought $25,000 worth of shares in the company back then? In 2021, Abbott generated $7.7 billion in revenue from its COVID-19 testing products, which accounted for 18% of its $43.1 billion in total sales.
© 2022 Yahoo. All rights reserved.
